Literature DB >> 20015441

[Effects of Astragalus injection and its ingredients on proliferation and Akt phosphorylation of breast cancer cell lines].

Ying Deng1, Hong-feng Chen.   

Abstract

OBJECTIVE: To observe the effects of Astragalus injection, astragaloside IV and formononetin on proliferation and Akt phosphorylation of basal-like human breast carcinoma cell lines MDA-MB-468 and MDA-MB-231.
METHODS: The effects of different concentrations of Astragalus injection, astragaloside IV and formononetin on proliferation of breast cancer cell lines were assayed by methyl thiazolyl tetrazolium (MTT) assay, and their effects on phospho-Akt were assayed by in-cell Western blot method.
RESULTS: The results of the MTT assay showed that the best concentrations of Astragalus injection, astragaloside IV, formononetin and astragaloside IV plus formononetin were 1 g/mL, 80 microg/mL, 40 microg/mL and 10 microg/mL plus 40 microg/mL respectively. After 1- or 2-day culture, Astragalus injection, astragaloside IV, formononetin and astragaloside IV plus formononetin decreased the expressions of p-Akt (Thr 308) and p-Akt (Ser 473) in MDA-MB-468 cells. Formononetin and astragaloside IV plus formononetin down-regulated the expression of p-Akt (Thr 308) protein in MDA-MB-231 cells after 1- and 2-day culture, but had no effects on the expression of p-Akt (Ser 473) protein in MDA-MB-231 cells.
CONCLUSION: Astragalus injection, astragaloside IV and formononetin can inhibit proliferation of breast cancer cell lines MDA-MB-468 and MDA-MB-231, and the antiproliferation effects vary according to their concentrations. And the antiproliferation mechanisms may be related to their down-regulation effects on Akt phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20015441     DOI: 10.3736/jcim20091216

Source DB:  PubMed          Journal:  Zhong Xi Yi Jie He Xue Bao        ISSN: 1672-1977


  6 in total

1.  Reducing postsurgical exudate in breast cancer patients by using San Huang decoction to ameliorate inflammatory status: a prospective clinical trial.

Authors:  Z Y Zhu; J X Xue; L X Yu; W H Bian; Y F Zhang; K C Sohn; I H Shin; C Yao
Journal:  Curr Oncol       Date:  2018-12-01       Impact factor: 3.677

Review 2.  A systematic review of anticancer effects of radix astragali.

Authors:  Yeehong Jung; Uimin Jerng; Sookyung Lee
Journal:  Chin J Integr Med       Date:  2015-12-07       Impact factor: 1.978

3.  Yiqi formula enhances the antitumor effects of erlotinib for treatment of triple-negative breast cancer xenografts.

Authors:  Ming-Juan Liao; Mei-Na Ye; Rui-Juan Zhou; Jia-Yu Sheng; Hong-Feng Chen
Journal:  Evid Based Complement Alternat Med       Date:  2014-10-19       Impact factor: 2.629

4.  Chinese Herbal Medicine as an Adjunctive Therapy Ameliorated the Incidence of Chronic Hepatitis in Patients with Breast Cancer: A Nationwide Population-Based Cohort Study.

Authors:  Kuo-Chin Huang; Hung-Rong Yen; Jen-Huai Chiang; Yuan-Chih Su; Mao-Feng Sun; Hen-Hong Chang; Sheng-Teng Huang
Journal:  Evid Based Complement Alternat Med       Date:  2017-10-30       Impact factor: 2.629

5.  Based on network pharmacology and molecular docking to predict the mechanism of Huangqi in the treatment of castration-resistant prostate cancer.

Authors:  Zesen Lin; Zechao Zhang; Xuejin Ye; Min Zhu; Zhihong Li; Yu Chen; Shuping Huang
Journal:  PLoS One       Date:  2022-05-20       Impact factor: 3.240

6.  A systems biology approach to uncovering pharmacological synergy in herbal medicines with applications to cardiovascular disease.

Authors:  Xia Wang; Xue Xu; Weiyang Tao; Yan Li; Yonghua Wang; Ling Yang
Journal:  Evid Based Complement Alternat Med       Date:  2012-11-29       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.